PPPatrick G. A. Pedrioli

Patrick G. A. Pedrioli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Patrick G. A. Pedrioli has a total of 135 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MultiOmicsAgent: Guided Extreme Gradient-Boosted Decision Trees-Based Approaches for Biomarker-Candidate Discovery in Multiomics Data

    by Jens Settelmeier, Sandra Goetze, Julia Boshart, Jianbo Fu, Amanda Khoo, Sebastian N. Steiner, Martin Gesell, Jacqueline Hammer, Peter J. Schüffler, Diyora Salimova, et al.

    MultiOmicsAgent (MOAgent) is an innovative, Python-based open-source tool for biomarker discovery, utilizing machine learning techniques, specifically extreme gradient-boosted decision trees, to process multiomics data. With its cross-platform compatibility, user-oriented graphical interface, and well-documented API, MOAgent not only meets the needs of both coding professionals and those new to machine learning but also addresses common data analysis challenges like normalization, data incompleteness, class imbalances and data leakage between disjoint data splits. MOAgent″s guided data analysis strategy opens up data-driven insights from digitized clinical biospecimen cohorts, making advanced data analysis accessible and reliable for a wide audience.


  • Open Access

    Paediatric Personalized Research Network Switzerland (SwissPedHealth): a joint paediatric national data stream

    by Rebeca Mozun, Fabiën N Belle, Andrea Agostini, Matthias R Baumgartner, Jacques Fellay, Christopher B Forrest, D Sean Froese, Eric Giannoni, Sandra Goetze, Kathrin Hofmann, et al.

    Introduction Children represent a large and vulnerable patient group. However, the evidence base for most paediatric diagnostic and therapeutic procedures remains limited or is often inferred from adults. There is an urgency to improve paediatric healthcare provision based on real-world evidence generation. Digital transformation is a unique opportunity to shape a data-driven, agile, learning healthcare system and deliver more efficient and personalised care to children and their families. The goal of Paediatric Personalized Research Network Switzerland (SwissPedHealth) is to build a sustainable and scalable infrastructure to make routine clinical data from paediatric hospitals in Switzerland interoperable, standardised, quality-controlled, and ready for observational research, quality assurance, trials and health-policy creation. This study describes the design, aims and current achievements of SwissPedHealth. Methods and analysis SwissPedHealth was started in September 2022 as one of four national data streams co-funded by the Swiss Personalized Health Network (SPHN) and the Personalized Health and Related Technologies (PHRT). SwissPedHealth develops modular governance and regulatory strategies and harnesses SPHN automatisation procedures in collaboration with clinical data warehouses, the Data Coordination Center, Biomedical Information Technology Network, and other SPHN institutions and funded projects. The SwissPedHealth consortium is led by a multisite, multidisciplinary Steering Committee, incorporating patient and family representatives. The data stream contains work packages focusing on (1) governance and implementation of standardised data collection, (2) nested projects to test the feasibility of the data stream, (3) a lighthouse project that enriches the data stream by integrating multi-omics data, aiming to improve diagnoses of rare diseases and 4) engagement with families through patient and public involvement activities and bioethics interviews. Ethics and dissemination The health database regulation of SwissPedHealth was approved by the ethics committee (AO_2022-00018). Research findings will be disseminated through national and international conferences and publications in peer-reviewed journals, and in lay language via online media and podcasts.


  • Open Access

    MultiOmicsAgent: Guided extreme gradient-boosted decision trees-based approaches for biomarker-candidate discovery in multi-omics data

    by Jens Settelmeier, Sandra Goetze, Julia Boshart, Jianbo Fu, Sebastian N. Steiner, Martin Gesell, Peter J. Schüffler, Diyora Salimova, Patrick G. A. Pedrioli, Bernd Wollscheid

    MultiOmicsAgent (MOAgent) is an innovative, Python based open-source tool for biomarker discovery, utilizing machine learning techniques specifically extreme gradient-boosted decision trees to process multi-omics data. With its cross-platform compatibility, user-oriented graphical interface and a well-documented API, MOAgent not only meets the needs of both coding professionals and those new to machine learning but also addresses common data analysis challenges like data incompleteness, class imbalances and data leakage between disjoint data splits. MOAgent’s guided data analysis strategy opens up data-driven insights from digitized clinical biospecimen cohorts and makes advanced data analysis accessible and reliable for a wide audience. Biographical Note Jens Settelmeier, Julia Boshart, Martin Gesell are Ph.D. candidates, Jianbo Fu, Sebastian N. Steiner are Post Doc candidates and Sandra Goetze, Patrick Pedrioli senior scientists at the Institute of Translational Medicine at Health Sciences and Technology department at ETH Zürich, Switzerland, within Professor Bernd Wollscheid’s research group who has been working in the fields of bioinformatics, clinical multi-omics with a focus on spatial cell surface proteomics. Peter J. Schüffler is professor at the institute of Pathology at the TU Munich, Germany and has been working in the field of digital pathology and clinical multi-modal studies. Diyora Salimova is junior professor at the department of Applied Mathematics at the Albert-Ludwigs-University of Freibug, Germany and has been working in the field of stochastic processes, approximation theory and machine learning related topics. Key Points MOAgent enables a guided biomarker-candidate discovery in multi-omics studies, providing a graphical interface and well-documented API. A user can run MOAgent on a personal computer without the requirement of coding a single line. MOAgent is a Python-based solution for biomarker-candidate discovery, using machine learning to analyze multi-omics data. MOAgent can address challenges like data incompleteness and class imbalances, ensuring reliable analysis. MOAgent makes advanced data analysis accessible, enhancing insights from clinical data.


  • Open Access

    Paediatric Personalized Research Network Switzerland (SwissPedHealth): A Joint Paediatric National Data Stream

    by Rebeca Mozun, Fabiën N. Belle, Andrea Agostini, Matthias R. Baumgartner, Jacques Fellay, Christopher B. Forrest, D. Sean Froese, Eric Giannoni, Sandra Goetze, Katrin Hofmann, et al.

    Introduction Children represent a large and vulnerable patient group. However, the evidence-base for most paediatric diagnostic and therapeutic procedures remains limited or is often inferred from adults. There is urgency to improve paediatric health care provision based on real-world evidence generation. The digital transformation is a unique opportunity to shape a data-driven, agile, learning health care system and deliver more efficient and personalized care to children and their families. The goal of SwissPedHealth is to build a sustainable and scalable infrastructure to make routine clinical data from paediatric hospitals in Switzerland interoperable, standardized, quality-controlled, and ready for observational research, quality assurance, trials, and health-policy creation. This paper describes the design, aims, and current achievements of SwissPedHealth. Methods and analysis SwissPedHealth started in September 2022 as one of four National Data Streams co-funded by the Swiss Personalized Health Network (SPHN) and the Personalized Health and Related Technologies (PHRT). SwissPedHealth develops modular governance and regulatory strategies, and harnesses SPHN automatization procedures, in collaboration with clinical data warehouses, the Data Coordination Center, Biomedical Information Technology Network, and other SPHN institutions and funded projects. The SwissPedHealth consortium is led by a multi-site, multi-disciplinary Steering Committee incorporating patient and family representatives. The data stream contains work packages focusing on: 1) governance and implementation of standardized data collection, 2) nested projects to test the feasibility of the data stream, 3) a lighthouse project that enriches the data stream by integrating multi-omics data, aiming to improve diagnoses of rare diseases, and 4) engagement with families through patient and public involvement activities and bioethics interviews. Ethics and dissemination The health database regulation of SwissPedHealth was approved by the ethics committee (AO_2022-00018). Research findings will be disseminated through national and international conferences, publications in peer-reviewed journals and in lay language via online media and podcasts. ARTICLE SUMMARY ⍰ The paediatric national data stream SwissPedHealth focuses on routine clinical data from children at Swiss University Children’s Hospitals, spans disciplines and is built in a scalable and modular way in terms of governance, data infrastructure, and patient and public involvement, to enable a gradual increase in coverage of the Swiss child population. ⍰ SwissPedHealth strives to increase readiness for quality improvement, research, and personalized paediatric health care. ⍰ SwissPedHealth’s infrastructure aligns with the national frameworks, safeguarding data security and adhering to a standard interoperability framework based on the Resource Description Framework (RDF). ⍰ SwissPedHealth seeks to explore integration of data from external sources such as federal statistics, cohorts, and registries, which have their own governance and data formats. • SwissPedHealth investigates the use of multi-omics workflows to improve diagnosis of rare diseases in children with life-threatening phenotypes

  • Open Access

    PRAMEL7 and CUL2 decrease NuRD stability to establish ground-state pluripotency

    by Meneka Rupasinghe, Cristiana Bersaglieri, Deena M Leslie Pedrioli, Patrick Ga Pedrioli, Martina Panatta, Michael O Hottiger, Paolo Cinelli, Raffaella Santoro

    Pluripotency is established in E4.5 preimplantation epiblast. Embryonic stem cells (ESCs) represent the immortalization of pluripotency, however, their gene expression signature only partially resembles that of developmental ground-state. Induced PRAMEL7 expression, a protein highly expressed in the ICM but lowly expressed in ESCs, reprograms developmentally advanced ESC+serum into ground-state pluripotency by inducing a gene expression signature close to developmental ground-state. However, how PRAMEL7 reprograms gene expression remains elusive. Here we show that PRAMEL7 associates with Cullin2 (CUL2) and this interaction is required to establish ground-state gene expression. PRAMEL7 recruits CUL2 to chromatin and targets regulators of repressive chromatin, including the NuRD complex, for proteasomal degradation. PRAMEL7 antagonizes NuRD-mediated repression of genes implicated in pluripotency by decreasing NuRD stability and promoter association in a CUL2-dependent manner. Our data link proteasome degradation pathways to ground-state gene expression, offering insights to generate in vitro models to reproduce the in vivo ground-state pluripotency.


  • Open Access

    PCfun: a hybrid computational framework for systematic characterization of protein complex function

    by Varun S Sharma, Andrea Fossati, Rodolfo Ciuffa, Marija Buljan, Evan G Williams, Zhen Chen, Wenguang Shao, Patrick G A Pedrioli, Anthony W Purcell, María Rodríguez Martínez, et al.

    In molecular biology, it is a general assumption that the ensemble of expressed molecules, their activities and interactions determine biological function, cellular states and phenotypes. Stable protein complexes—or macromolecular machines—are, in turn, the key functional entities mediating and modulating most biological processes. Although identifying protein complexes and their subunit composition can now be done inexpensively and at scale, determining their function remains challenging and labor intensive. This study describes Protein Complex Function predictor (PCfun), the first computational framework for the systematic annotation of protein complex functions using Gene Ontology (GO) terms. PCfun is built upon a word embedding using natural language processing techniques based on 1 million open access PubMed Central articles. Specifically, PCfun leverages two approaches for accurately identifying protein complex function, including: (i) an unsupervised approach that obtains the nearest neighbor (NN) GO term word vectors for a protein complex query vector and (ii) a supervised approach using Random Forest (RF) models trained specifically for recovering the GO terms of protein complex queries described in the CORUM protein complex database. PCfun consolidates both approaches by performing a hypergeometric statistical test to enrich the top NN GO terms within the child terms of the GO terms predicted by the RF models. The documentation and implementation of the PCfun package are available at https://github.com/sharmavaruns/PCfun. We anticipate that PCfun will serve as a useful tool and novel paradigm for the large-scale characterization of protein complex function.


  • Open Access

    Diagnostics and correction of batch effects in large‐scale proteomic studies: a tutorial

    by Jelena Čuklina, Chloe H Lee, Evan G Williams, Tatjana Sajic, Ben C Collins, María Rodríguez Martínez, Varun S Sharma, Fabian Wendt, Sandra Goetze, Gregory R Keele, et al.

    Advancements in mass spectrometry‐based proteomics have enabled experiments encompassing hundreds of samples. While these large sample sets deliver much‐needed statistical power, handling them introduces technical variability known as batch effects. Here, we present a step‐by‐step protocol for the assessment, normalization, and batch correction of proteomic data. We review established methodologies from related fields and describe solutions specific to proteomic challenges, such as ion intensity drift and missing values in quantitative feature matrices. Finally, we compile a set of techniques that enable control of batch effect adjustment quality. We provide an R package, "proBatch", containing functions required for each step of the protocol. We demonstrate the utility of this methodology on five proteomic datasets each encompassing hundreds of samples and consisting of multiple experimental designs. In conclusion, we provide guidelines and tools to make the extraction of true biological signal from large proteomic studies more robust and transparent, ultimately facilitating reliable and reproducible research in clinical proteomics and systems biology.


  • Open Access

    The proteome of remyelination is different from that of developmental myelination

    by Joana Paes de Faria, Maria M. Azevedo, Damaris Bausch-Fluck, Ana Seixas, Helena S. Domingues, Maria A. Monteiro, Patrick G.A. Pedrioli, Eduarda Lopes, Rui Fernandes, Chao Zhao, et al.

    Loss of myelin underlies the pathology of several neurological disorders of diverse etiology. CNS remyelination by adult oligodendrocyte progenitor cells (OPCs) can occur but it differs from developmental myelination carried out by neonatal OPCs. We asked whether the myelin proteome of remyelinated regions is changed. We compared the myelin proteome formed during development to the remyelination proteome attained after lysolecithin-induced demyelination in the mouse spinal cord. Mass-spectrometry analysis of iTRAQ labelled myelin protein lysates showed that the proteome of remyelination is different from that of developmental myelination, leading to profound changes in myelin protein content. Aside from known mediators of oligodendrocyte differentiation, we found proteome alterations included modulators of metabolism, cell signaling and actin cytoskeleton dynamics. Downregulating one candidate (FSCN1/Fascin1) was sufficient to partially hamper oligodendrocytes in-vitro . In summary, we identify the difference in the proteome of remyelinating oligodendrocytes as a novel potential contributor to the pathophysiology of demyelinating disorders, thus providing new potential therapeutic targets for future studies.


  • Open Access

    Differential Diagnosis of Preeclampsia Based on Urine Peptidome Features Revealed by High Resolution Mass Spectrometry

    by Alexey S. Kononikhin, Natalia V. Zakharova, Viktoria A. Sergeeva, Maria I. Indeykina, Natalia L. Starodubtseva, Anna E. Bugrova, Kamila T. Muminova, Zulfia S. Khodzhaeva, Igor A. Popov, Wenguang Shao, et al.

    Preeclampsia (PE) is a severe pregnancy complication, which may be considered as a systemic response in the second half of pregnancy to physiological failures in the first trimester, and can lead to very serious consequences for the health of the mother and fetus. Since PE is often associated with proteinuria, urine proteomic assays may represent a powerful tool for timely diagnostics and appropriate management. High resolution mass spectrometry was applied for peptidome analysis of 127 urine samples of pregnant women with various hypertensive complications: normotensive controls (n = 17), chronic hypertension (n = 16), gestational hypertension (n = 15), mild PE (n = 25), severe PE (n = 25), and 29 patients with complicated diagnoses. Analysis revealed 3869 peptides, which mostly belong to 116 groups with overlapping sequences. A panel of 22 marker peptide groups reliably differentiating PE was created by multivariate statistics, and included 15 collagen groups (from COL1A1, COL3A1, COL2A1, COL4A4, COL5A1, and COL8A1), and single loci from alpha-1-antitrypsin, fibrinogen, membrane-associated progesterone receptor component 1, insulin, EMI domain-containing protein 1, lysine-specific demethylase 6B, and alpha-2-HS-glycoprotein each. ROC analysis of the created model resulted in 88% sensitivity, 96.8% specificity, and receiver operating characteristic curve (AUC) = 0.947. Obtained results confirm the high diagnostic potential of urinary peptidome profiling for pregnancy hypertensive disorders diagnostics.


  • Open Access

    Sensitive and reproducible determination of clinical HDL proteotypes

    by Sandra Goetze, Kathrin Frey, Lucia Rohrer, Silvija Radosavljevic, Jan Kruetzfeldt, Ulf Landmesser, Marco Bueter, Patrick G. A. Pedrioli, Arnold von Eckardstein, Bernd Wollscheid

    Background: High-density lipoprotein (HDL) is a heterogenous mixture of blood-circulating multimolecular particles containing many different proteins, lipids, and RNAs. Recent advancements in mass spectrometry-based proteotype analysis strategies enable the sensitive and reproducible quantification of proteins across large patient cohorts. Methods: HDL particles were isolated from plasma of more than 300 healthy individuals or patients with a multiplicity of physiological HDL states. From these, peptides were extracted and HDL proteome spectral libraries were generated. This is a prerequisite for using data-independent acquisition (DIA) strategies to analyze HDL particles from clinical cohorts using mass spectrometry. Results: The resulting HDL proteome spectral libraries consist of 296 protein groups and 341 peptidoforms of potential biological significance identified with high confidence. We used the HDL proteome libraries to evaluate HDL proteotype differences in between healthy individuals and patients suffering from diabetes mellitus type 2 (T2DM) and/or coronary heart disease (CHD). Bioinformatic interrogation of the data revealed significant quantitative differences in the HDL proteotypes including a significant depletion of phosphatidylinositol-glycan-specific phospholipase D (PHLD) from disease-derived HDL particles. Conclusion: The DIA-based HDL proteotyping strategy enabled sensitive and reproducible digitization of HDL proteotypes derived from patient cohorts and provides new insights into the composition of HDL particles as a rational basis to decode structure-function-disease relationships of HDL. List of human genes and protein names discussed in the paper: - APOA1 (Apolipoprotein A-I) - APOA2 (Apolipoprotein A-II) - APOE (Apolipoprotein E) - APOC3 (Apolipoprotein C3) - CLUS (Clusterin) - PHLD (Phosphatidylinositol-glycan-specific phospholipase D) - PON1 (Serum paraoxonase/arylesterase 1) - PON3 (Serum paraoxonase/lactonase 3) - PSPB (Pulmonary surfactant-associated protein B) - RAB1B (Ras-related protein Rab-1B) - RAB6A (Ras-related protein Rab-6A) - RB11A/B (Ras-related protein Rab-11A/B) - RP1BL (Ras-related protein Rap-1b-like protein) - RAB10 (Ras-related protein Rab-10) - SAA1 (Serum amyloid A-1 protein) - SAA2 (Serum amyloid A-2 protein) - SAA4 (Serum amyloid A-4 protein) - SCRB1 (Scavenger receptor class B member 1)